European Commission approves NewAmsterdam/Menarini obicetrapib therapies
European Commission approval granted for NewAmsterdam Pharma’s obicetrapib monotherapy (Ubeslo®) and obicetrapib plus ezetimibe fixed-dose combination (Evlarco®), per TradingView News.
Story updates
02:58:56 PM UTC
SquawkNews
The European Commission approved Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib + ezetimibe) for primary hypercholesterolaemia and mixed dyslipidaemia, the first global approval of obicetrapib. Menarini will commercialize in Europe; NAMS is eligible for tiered royalties.Material DetailsC…
The European Commission has approved Ubeslo, obicetrapib monotherapy, and Evlarco, obicetrapib plus ezetimibe, for primary hypercholesterolaemia and mixed dyslipidaemia, marking the first global approval of obicetrapib. Menarini will commercialize the therapies in Europe, and NAMS is eligible for tiered royalties.